Taylor CW - Search Results

1

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

Meyskens FL Jr, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK. Meyskens FL Jr, et al. Among authors: taylor cw. J Natl Cancer Inst. 1995 Nov 15;87(22):1710-3. doi: 10.1093/jnci/87.22.1710. J Natl Cancer Inst. 1995. PMID: 7473820 Clinical Trial. No abstract available.

2

Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro.

Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE. Hersh EM, et al. Among authors: taylor cw. J Natl Cancer Inst. 1992 Aug 19;84(16):1238-44. doi: 10.1093/jnci/84.16.1238. J Natl Cancer Inst. 1992. PMID: 1640482

3

A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer.

Taylor CW, Chase EM, Whitehead RP, Rinehart JJ, Neidhart JA, Gonzalez R, Bunn PA, Hersh EM. Taylor CW, et al. J Immunother (1991). 1992 Apr;11(3):176-83. doi: 10.1097/00002371-199204000-00004. J Immunother (1991). 1992. PMID: 1515422 Clinical Trial.

4

A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors.

Taylor CW, Dorr RT, Fanta P, Hersh EM, Salmon SE. Taylor CW, et al. Cancer Chemother Pharmacol. 2001;47(1):83-8. doi: 10.1007/s002800000207. Cancer Chemother Pharmacol. 2001. PMID: 11221967 Clinical Trial.

5

A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy.

Taylor CW, Modiano MR, Woodson ME, Marcus SG, Alberts DS, Hersh EM. Taylor CW, et al. Semin Oncol. 1992 Apr;19(2 Suppl 3):185-90. Semin Oncol. 1992. PMID: 1557645 Clinical Trial.

6

Human tumor models in the severe combined immune deficient (scid) mouse.

Paine-Murrieta GD, Taylor CW, Curtis RA, Lopez MH, Dorr RT, Johnson CS, Funk CY, Thompson F, Hersh EM. Paine-Murrieta GD, et al. Among authors: taylor cw. Cancer Chemother Pharmacol. 1997;40(3):209-14. doi: 10.1007/s002800050648. Cancer Chemother Pharmacol. 1997. PMID: 9219503

7

Phase I study of low-dose cyclophosphamide and recombinant interleukin-2 for the treatment of advanced cancer.

Verdi CJ, Taylor CW, Croghan MK, Dalke P, Meyskens FL, Hersh EM. Verdi CJ, et al. Among authors: taylor cw. J Immunother (1991). 1992 May;11(4):286-91. doi: 10.1097/00002371-199205000-00007. J Immunother (1991). 1992. PMID: 1599914 Free article. Clinical Trial.

8

Suppression of human lymphoma development in the severe combined immune-deficient mouse by imexon therapy.

Hersh EM, Grogan TM, Funk CY, Taylor CW. Hersh EM, et al. Among authors: taylor cw. J Immunother Emphasis Tumor Immunol. 1993 Feb;13(2):77-83. doi: 10.1097/00002371-199302000-00001. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8391308

9

Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency.

Taylor CW, Grogan TM, Lopez MH, Leong SP, Odeleye A, Feo-Zuppardi FJ, Hersh EM. Taylor CW, et al. Lab Invest. 1992 Jul;67(1):130-7. Lab Invest. 1992. PMID: 1625443

10

Comparison of 4- and 24-hour intravenous infusion schedules for granulocyte-macrophage colony-stimulating factor.

Wong L, Taylor CW, Radwanski E, Hersh EM, Salmon SE. Wong L, et al. Among authors: taylor cw. J Immunother Emphasis Tumor Immunol. 1995 Jul;18(1):57-65. doi: 10.1097/00002371-199507000-00008. J Immunother Emphasis Tumor Immunol. 1995. PMID: 8535572 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

436 results

Search Page

Filters